Related Experiment Video
Updated: Aug 5, 2026
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Potential Clinical Impact of Revised Pulmonary Hypertension Definitions at Moderate Altitude
August Longino1, Alexandra N Fuher1, Kaitlyn Mcleod1
1Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Background:
Pulmonary hypertension (PH) and precapillary PH definitions have been revised. Before 2018, PH was defined by a mean pulmonary arterial pressure ≥ 25 mm Hg, and precapillary PH was defined by a pulmonary vascular resistance ≥ 3 Wood units and a pulmonary arterial wedge pressure ≤ 15 mm Hg. In 2018, the mean pulmonary arterial pressure threshold dropped to 20 mm Hg. In 2022, the diagnostic threshold of pulmonary vascular resistance dropped from ≥ 3 to > 2 Wood units. The implications of the revised definitions at altitude remain unclear.
Research Question:
Do revised definitions capture similar patients at altitude and sea level?
Study Design And Methods:
We analyzed hemodynamic data from patients' right heart catheterization procedures at 1,609 m. We extracted clinical data on PH diagnosis, progression, and mortality from the electronic medical record and the National Death Index.
Results:
A total of 2,382 patients were analyzed. Mean resident altitude ± SD was 1,631.1 ± 674 m. Pre-2018, 1,412 patients (59.2%) had PH and 508 patients (21.3%) had precapillary PH. Applying the post-2018 definition resulted in 307 patients (12.8%) being diagnosed with PH, including 86 (3.6%) with a diagnosis of precapillary PH. Applying the post-2022 definition resulted in 306 patients (12.8%) being diagnosed with precapillary PH (P < .05). Patients newly diagnosed with PH had age- and sex-adjusted mortality lower than patients with pre-2018 PH (hazard ratio [HR], 0.67; 95% CI, 0.54-0.83; P < .001) and higher than patients without PH (HR, 0.46; 95% CI, 0.39-0.56). Compared with patients with pre-2018 precapillary PH, patients with post-2022 precapillary PH demonstrated mortality (HR, 0.7; 95% CI, 0.53-0.91; P = .009). There was no significant difference in mortality or progression between patients with post-2018 and pre-2018 precapillary PH.
Interpretation:
In this study, at moderate altitude, revised definitions of PH identified patients with a greater likelihood of mortality, similar to sea level findings. The post-2022 definition of precapillary PH increased the prevalence of precapillary PH, identifying a population with lower mortality, without progressive disease. Further research on this population is needed.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:29Pulmonary Embolism I: Introduction
01:19Pulmonary Embolism I: Introduction
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...